Lung and thoracic highlights
Paper picks, newest first.
November 2026
- Is the next generation of KRAS G12C inhibitors changing the treatment landscape in advanced NSCLC?
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
Publication pick. NEJM. November 3, 2026.
October 2026
- A 0.42 hazard ratio for death in extensive-stage small-cell lung cancer.
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
Publication pick. NEJM. October 30, 2026.
- Can a blood test detect cancer earlier—but still fail to demonstrate clinical utility?
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
- Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy?
SKYSCRAPER-02C A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China
Publication pick. Journal of Thoracic Oncology. October 7, 2026.
- Does adding immunotherapy to SBRT actually improve outcomes in early-stage, medically inoperable NSCLC or simply add toxicity?
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914)
Publication pick. The Lancet. October 5, 2026.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.



